Cargando…
Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic
Emergency authorized coronavirus disease 2019 (COVID-19)–neutralizing monoclonal antibodies can aid outpatients with mild to moderate COVID-19 infection. Many report barriers to adequate distribution and uptake. We present our model for distribution in a large health system as well as early lessons...
Autores principales: | Bariola, J Ryan, McCreary, Erin K, Khadem, Tina, Snyder, Graham M, Wadas, Richard J, Nace, David A, White, Douglas B, Yealy, Donald M, Schmidhofer, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083628/ https://www.ncbi.nlm.nih.gov/pubmed/34322560 http://dx.doi.org/10.1093/ofid/ofab151 |
Ejemplares similares
-
Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021) -
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021) -
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days
por: McCreary, Erin K., et al.
Publicado: (2022) -
Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022) -
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization
por: Huang, David T., et al.
Publicado: (2021)